Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women
Status:
Completed
Trial end date:
2017-10-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the immunogenicity and safety of Boostrix™ when
compared to a placebo given during 27-36 weeks of gestation in healthy women aged 18-45
years. Infants born to mothers enrolled in this study will be followed-up in two separate
clinical studies: 201330 [DTPA (BOOSTRIX)-048 PRI] and 201334 [DTPA (BOOSTRIX)-049 BST: 048].